SCHEMBL3097229

SCHEMBL3097229

CSc1ccc(Cc2[c]oc3ccccc23)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VKORC1 Q9BQB6 1/20 0.48
SLC6A4 P31645 5/20 0.42
SLC6A2 P23975 2/20 0.42
SLC6A3 Q01959 2/20 0.42
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
HPGD P15428 2/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
RAB9A P51151 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
TBXA2R P21731 1/20 0.35
PTGER3 P43115 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3092337 0.83 TP53 (0.38) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL3074399 0.83 NPC1 (0.35) SMN1; SMN2ALDH1A1MAPTRAB9AATM
SCHEMBL2197293 0.82 CALM1 (0.41) MEN1KMT2AMAPTHPGD
SCHEMBL3084454 0.79 MAOB (0.50) VKORC1MEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL3091034 0.79 TNKS (0.38) SMN1; SMN2ALDH1A1RAB9ACYP2C9
SCHEMBL3085524 0.70 SLC6A4 (0.42) VKORC1SLC6A4SLC6A2SLC6A3MEN1
SCHEMBL3090755 0.69 SLC6A4 (0.41) VKORC1SLC6A4SLC6A2SLC6A3MEN1
SCHEMBL27613417 0.68 SLC6A4 (0.58) SLC6A4SLC6A2SLC6A3MEN1KMT2A
SCHEMBL13026656 0.68 SLC6A4 (0.56) SLC6A4SLC6A2SLC6A3MEN1KMT2A
SCHEMBL10514896 0.68 L3MBTL1 (0.33) KMT2ASMN1; SMN2KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207134-B2 Fused ring spiroketal derivative and use thereof as anti-diabetic drug CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-06-26 US disclosed
US-20100234609-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-09-16 US disclosed
EP-2048152-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234609-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG REN, WNK1, GCKR VKORC1 181/4885SLC6A4 2602/4885SLC6A2 3399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.